Please assess the completion status of the following clinical trial:

Trial Title: Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-75 years of age, of either sex or any race~* Clinical history of at least 2 lipomas for at least one year~* Lipomas diagnosed as benign~* Two lipomas on distinctly separate parts of the body, or on the torso if 30 cm apart, with easily definable edges~* Each lipoma is a single mass with easily definable edges~* Lipomas are 5 to 24 cm squared~* Women of childbearing potential must use an acceptable method of birth control~Exclusion Criteria:~* Lipomas on the head, neck, hand or foot, or female breast~* Women who are nursing or pregnant~* Multi-lobular lipomas~* Subjects who have received an investigational drug within 30 days before receiving the first dose of study drug in this study~* Subjects with a known allergy to collagenase or any of the inactive ingredients in XIAFLEX~* Subjects with uncontrolled diabetes, hypertension, or thyroid disease, or any medical condition that would make the subject unsuitable for enrollment~* Subjects having prior treatment or trauma of the lipoma that could interfere with study assessments~* Subjects with a history of connective tissue diseases, rheumatological diseases~* Subjects taking anticoagulants or planning to receive anticoagulants (except for lo dose aspirin and over-the-counter nonsteroidal anti-inflammatory drugs) within 7 days of injection of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- AA4500 (Type: ACTIVE_COMPARATOR): single injection of 0.58 mg study drug
- Placebo (Type: PLACEBO_COMPARATOR): single injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).